Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1

T Abe1, K Koike1, T Ohta1, T Kubo1, M Wada1, K Kohno1, T Mori2, K Hidaka1 and M Kuwano1

1Department of Biochemistry, Kyushu University School of Medicine, Fukuoka 812-82; 2Department of Neurosurgery, Oita Medical University, Oita 879-55; 3Department of Surgery, Saga Medical School, Saga 849, Japan.

Summary Multidrug resistance phenotypes in human tumours are associated with the overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene, and also with that of the non-P-glycoprotein-mediated multidrug resistance gene, MRP, which encodes a 190 kDa membrane ATP-binding protein. We have previously reported that overexpression of MRP appears to be responsible for spontaneous multidrug resistance in some human glioma cell lines (Abe et al., Int. J. Cancer, 58, 860–864, 1994). In this study, we investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug resistance such as verapamil, a biscauline alkaloid (cepharanthine), and a dihydropyridine analogue (NIK250) could also reverse multidrug resistance in human glioma cells. The glioma cell lines were the two MRP-expressing cell lines, T98G and IN500, an MDR1-expressing cell line, CCF-STTG1, and the MRP/MDR1-non-expressing cell line, IN157. Verapamil and NIK250 almost completely reversed drug resistance to vincristine, etoposide and doxorubicin in T98G cells, while they also reversed drug resistance to vincristine and etoposide, but only partially to doxorubicin in IN500 cells. Cepharanthine as well as verapamil and NIK250 reversed vincristine resistance in CCF-STTG1 cells, but cepharanthine only partially reversed drug resistance in T98G and IN500 cells. The cellular accumulation of [3H]etoposide increased about 2- and 3-fold compared with control in T98G cells in the presence of verapamil and NIK250, respectively. Furthermore, the release of doxorubicin from the nuclei of T98G cells was blocked by NIK250. However, NIK250 caused no apparent increase in vincristine accumulation in T98G cells. NIK250 or verapamil might exert inhibitory effects upon MRP function, resulting in a reversal of MRP-mediated spontaneous multidrug resistance in cultured human glioma cells.

Keywords: glioma; multidrug resistance; MRP; MDR1; dihydropyridine; verapamil

The appearance of multidrug-resistant tumours is a serious problem in cancer chemotherapy. The overexpression of a membrane P-glycoprotein (P-gp) with a molecular weight of 170 kDa, encoded by the MDR1 gene, is often associated with the acquisition of multidrug resistance (MDR) phenotypes (Bradley et al., 1988). Reduced drug retention in P-gp-overexpressing cells is due to the enhanced active efflux of anti-cancer agents. MDR1 is often overexpressed in various tumours in cancer patients (Goldstein et al., 1989). However, the expression of the MDR1-encoded P-gp is not always coupled with the acquisition of MDR in various human tumour cell lines. Cole et al. (1992) have recently isolated a gene named MRP from a doxorubicin-resistant small-cell lung carcinoma cell line with the MDR phenotype (Mirsiki et al., 1987). This MRP gene is amplified in some multidrug resistant cell lines (Krishnamachary and Center, 1993; Barrand et al., 1994). Zaman et al. (1993) have further demonstrated that MRP is 25-fold overexpressed in a P-gp small-cell lung cancer cell line, but not in other non-P-gp MDR cell lines derived from non-small-cell lung cancers. The human breast carcinoma cell line MCF7, which is selected for etoposide resistance, and which overexpresses the MRP gene, is resistant to etoposide and doxorubicin, and shows low-level cross-resistance to vincristine and mitoxantrone (Schneider et al., 1994). Furthermore, Grant et al. (1994) have demonstrated that HeLa cells transfected with an MRP expression vector display an increase in resistance to doxorubicin, vincristine and etoposide, but not to cisplatin. MRP is a member of the ATP-binding cassette (ABC) superfamily transport system proposed by Hyde et al. (1990), but MRP has minor sequence homology with the P-gp encoded by the human MDR1 gene (Cole et al., 1992). We have previously reported that two of seven glioma cell lines, IN500 and T98G, which have elevated MRP mRNA levels are resistant to multiple anti-cancer agents such as etoposide, vincristine and doxorubicin, and that there is decreased intracellular accumulation of etoposide (Abe et al., 1994a).

To reverse multidrug resistance, many agents have been investigated. Calcium channel blockers such as verapamil, nicipridine and others reportedly overcome drug resistance in vitro and vivo (Tsuro et al., 1981). The clinical use of calcium channel blockers, however, might pose a therapeutic problem because they are powerful vasodilators. We have reported that some dihydropyridine analogues can overcome multidrug resistance in cancer cell lines as well as in leukaemia-bearing mice (Kiue et al., 1990a,b; Kiue et al., 1991; Watanabe et al., 1991). We also reported that cepharanthine, a bisbenzylisoquinoline biscauline alkaloid, completely overcomes the resistance of multidrug-resistant sublines derived from human KB carcinoma cells (Shiraishi et al., 1987). NIK250 and other dihydropyridine analogues as well as cepharanthine and verapamil specifically inhibit the photoaffinity labelling of radioactive azidopine to P-gp of membrane vesicles of MDR1-overexpressing cancer cells, suggesting that they have high affinity for P-gp (Cornwell et al., 1987; Akiyama et al., 1988; Kiue et al., 1990b; Watanabe et al., 1991). On the other hand, it has been demonstrated that cyclosporin A and its derivatives, as well as verapamil, modify non-P-gp-mediated multidrug resistance, but their chemosensitisation is not effective (Slovak et al., 1988; Cole et al., 1989; Meijer et al., 1991; Barrand et al., 1993). In this study, we investigated whether NIK250 as well as verapamil and cepharanthine could potentiate etoposide, doxorubicin and vincristine in multidrug-resistant human glioma cell lines that overexpress the MRP gene in vitro.

Correspondence: T Abe
Received 10 January 1995; revised 8 March 1995; accepted 16 March 1995
Materials and methods

Tumour cell lines

The glioma cell lines IN157, IN500, T98G and CCF-STTG1, derived from patients with glioma, were studied (Abe et al., 1993, 1994a,b). These human glioma cell lines were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units ml\(^{-1}\) penicillin and 60 mg ml\(^{-1}\) kanamycin as described previously (Abe et al., 1993, 1994a).

Northern blot analysis

A human MRp cDNA probe (1 kb EcoRI fragment) was provided by SPC Cole (Queens University, Ontario, Canada) (Cole et al., 1992). Human MDR1 cDNA was from MM Gottesman (NCI, NIH, Bethesda, MD, USA), human topoisomerase I cDNA probe from O Koiwaki and T Andoh (Aichi Cancer Center, Nagoya, Japan) and human topoisomerase IIa probe (pBS-hTOP2) from JC Wang (Harvard University, USA). Northern blotting was performed as described previously (Abe et al., 1993; Kohno et al., 1994). Glioma cells were incubated in DMEM containing 10% FBS, and harvested cells were suspended in 4 ml guanidium thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarcosyl and 0.1 M β-mercaptoethanol. Thereafter, 2 ml sodium acetate (pH 4.0), water-saturated phenol and chloroform were successively added. After vigorous mixing, the samples were left on ice for 20 min, then centrifuged at 10 000 g for 20 min. The aqueous phase was separated into portions, mixed with isopropanol and stored at -20°C for 20 min. The samples were then centrifuged at 10 000 g for 20 min to obtain the RNA pellet, which was washed with 75% ethanol and dissolved in sterile, RNAse-free water. The RNA was fractionated through a 1% agarose gel containing 2.2 M formaldehyde and transferred onto a Nitran filter (Schleicher and Schuell). The mRNA levels were quantified by densitometry using a Fujix BAS 2000 bioimaging analyser (Fuji Photo Film, Tokyo, Japan).

Drug and chemicals

Doxorubicin was a gift from Kyowa Pharmaceuticals, Tokyo, Japan; vincristine was from Shinohog Pharmaceuticals, Tokyo, Japan; etoposide was from Nihon Kayaku, Tokyo, Japan; NIK250 (Figure 1) (Kiiue et al., 1990a, 1991; Watanabe et al., 1991) was from Nikken Chemicals, Saitama, Japan; Cepharantline (Figure 1) (Shiraiishi et al., 1987) was from Kaken Shoyaku, Tokyo, Japan; Verapamil was from Eizai, Tokyo, Japan, \(^{[3]}\)Hetoeposide (388 Ci mmol\(^{-1}\)) was obtained from Moravek Biochemicals (Brea, CA, USA) and \(^{[3]}\)Hvincristine (4.8 Ci mmol\(^{-1}\)) was obtained from New England Nuclear.

Cell survival by colony formation

Cell survival was determined by plating about 10\(^3\) cells in 35 mm dishes (Abe et al., 1994a) then adding various drugs 24 h later. After incubation for 7 days at 37°C, the number of colonies was counted after Giemsa staining. All drugs were freshly prepared in physiological saline or dimethylsulphoxide. All control experiments included the same amount of saline or dimethylsulphoxide. The 90% lethal dose (LD\(_{90}\)) for each glioma cell line was determined from dose–response curves. Relative resistance were determined from three separate experiments.

Drug accumulation

Cells (2 x 10\(^3\) per well; 24 well plate) were plated and incubated for 48 h at 37°C. After reaching subconfluence, the plates were incubated in ice in water at 4°C for 15 min and washed twice with ice-cold phosphate-buffered saline (PBS). The medium was then replaced with 200 ml of buffer (serum-free DMEM and 20 mM HEPES, pH 7.5) containing \(^{[3]}\)Hetoeposide and \(^{[3]}\)Hvincristine, and the cells were incubated at 37°C with or without verapamil, cepharantline or NIK250. The cells were then washed three times with ice-cold PBS, then 400 ml of 0.25 M sodium hydroxide was added, and the cells were incubated at 37°C for over 30 min. The cellular pellets were mixed thoroughly with 4 ml of Scintisol EX-H (Wako, Osaka, Japan) and the radioactivity was counted.

Fluorescent microscopy

Glioma cells in exponential growth were centrifuged, suspended in DMEM–10% FBS at 1 x 10\(^5\) ml\(^{-1}\), seeded onto glass slides and incubated at 37°C for 24 h. The cells were subsequently incubated in presence of doxorubicin 1 μg ml\(^{-1}\) with or without verapamil, cepharantline or NIK250 for 40 min at 37°C, then incubated in its absence with or without verapamil, cepharantline or NIK250 for 120 min at 37°C, followed by washing with ice-cold PBS twice, and mounted in 50% glycerol in PBS. The fluorescence of doxorubicin in the cells was examined by Leica fluorescence microscopy with a Bio-Rad laser scanning confocal imaging system (MRC-1000) as described previously (Abe et al., 1994a; Hasegawa et al., 1995).

Results

Drug resistance to several anti-cancer agents in four human glioma cell lines

We have previously reported overexpression of the MRp gene in the two human glioma cell lines, T98G and IN500, but not in IN157. The first two, but not the last, showed spontaneous drug resistance to multiple anti-cancer agents (Abe et al., 1994a). We examined the sensitivity of these three human glioma cell lines and another, CCF-STTG1, to various anti-cancer agents such as vincristine, doxorubicin and etoposide by colony formation assays. Dose–response curves of the cell lines to these agents were generated, and from these the LD\(_{50}\) was calculated. The relative resistance of T98G and IN500 to the three drugs is presented in Table 1. Both were 5.4- to 6.1-fold more resistant to vincristine, and 9.1- to 12.0-fold more resistant to doxorubicin and etoposide than IN157. CCF-STTG1 cells were around 10-fold more resistant to vincristine than IN157 cells, but the sensitivity to etoposide and doxorubicin was similar (Table 1).

Expression of MDR, MRp, DNA topoisomerase I and II α genes

Northern blot analysis was performed to determine whether the altered sensitivity of human glioma cell lines was due to altered expression of drug resistance-relevant genes such as MDR1, DNA topoisomerases I and IIa and MRp. Topoisomerase I and IIa were expressed at similar levels in IN157, IN500 and T98G, but at much lower levels in CCF-STTG1 (Figure 2, Table II). MDR1 mRNA was overexpressed only in CCF-STTG1 cells, but MRp mRNA was not (Figure 2, Table II). Consistent with a report by Cole et al. (1992), the MRp-specific probe hybridised to a 6.5 kb RNA species (Figure 2). In comparison with drug-sensitive IN157 cells, MRp mRNA was overexpressed 8- to 10-fold in IN500 and T98G cell lines, in good agreement with our previous study (Abe et al., 1994a). The multidrug-resistant phenotype in IN500 and T98G appeared to be rather closely correlated more with overexpression of MRp gene than with that of the MDR1 gene. Furthermore, vincristine resistance in CCF-STTG1 cells appeared to be mediated through the overexpression of the MDR1 gene.

Reversal effects by combination with cepharantline, verapamil or NIK 250, and drug accumulation

We examined whether cepharantline, verapamil or NIK250 could reverse drug resistance in the human glioma cell lines

Reversal agents of MRP- or MDR-mediated drug resistance

T Abe et al
Table I Drug sensitivity and reversal of multidrug resistance in glioma cells using colony formation assay.

| Combined drugs | Dose (μg ml⁻¹) | IN157 | T98G | IN500 | CCF-STTG1 |
|---------------|----------------|-------|------|-------|-----------|
|               | VCR⁶ | ETP⁷ | DOX⁸ | VCR  | ETP  | DOX  | VCR  | ETP  | DOX  |
| None          | 0.0  | 1.0  | 1.0  | 1.0  | 6.1  | 12.0 | 9.1  | 5.4  | 11.8 | 10.0 | 10.5 | 0.9  | 2.5  |
| Cepharanthine | 1.0  | 1.0  | 0.7  | 0.6  | 4.8  | 9.4  | 4.6  | 4.2  | 4.5  | 3.4  | 1.4  | 0.8  | 1.2  |
| Verapamil     | 5.0  | 0.9  | 0.8  | 0.8  | 1.0  | 1.6  | 2.0  | 1.6  | 1.5  | 3.2  | 1.2  | 0.9  | 1.4  |
| NIK250        | 10.0 | 0.6  | 0.6  | 0.5  | 1.0  | 0.9  | 1.4  | 1.4  | 1.4  | 3.0  | 0.8  | 0.5  | 0.9  |

*The sensitivity of glioma cell lines to various anti-cancer agents was examined by means of colony formation assays. Chemosensitising drugs cause less than 10% cytotoxicity when tested alone. VCR, vincristine; ETP, etoposide; DOX, doxorubicin. *Relative resistance to vincristine, etoposide and doxorubicin is presented when the 90% lethal dose (LD₉₀) for each cell line is divided by that for IN157 cells (LD₉₀ = 0.24 ± 0.06 ng ml⁻¹ for vincristine, 1.40 ± 1.1 ng ml⁻¹ for etoposide and 1.3 ± 0.2 ng ml⁻¹ for doxorubicin). *The concentration of cepharanthine was 1.0 μg ml⁻¹ for IN157, IN500 and T98G cells, and 0.4 μg ml⁻¹ for CCF-STTG1 cells.

Figure 1 Chemical structures of the 1,4-dihydropyridine compounds, NIK250 and cepharanthine.

IN157, T98G, IN500 and CCF-STTG1. Resistance to vincristine, etoposide and doxorubicin in T98G and IN500 cells was almost completely reversed when combined with verapamil or NIK250 (Table I). Combination with cepharanthine partially reversed resistance to these agents in T98G or IN500 cells, whereas drug resistance to vincristine in CCF-STTG1 cells was almost completely reversed when combined with cepharanthine.

The cellular accumulation of vincristine, etoposide and doxorubicin is often reduced in multidrug-resistant cell lines (Kohno et al., 1988; Matsuo et al., 1990). The reduced accumulation of etoposide appears to be involved in the relatively higher drug resistance of T98G (Abe et al., 1994a). The cellular accumulation of this drug was assayed after 30 and 60 min (Figure 3). The accumulation of [³H]etoposide in T98G cells reached steady-state levels within 30 min at 37°C, and cellular accumulation of [³H]etoposide in T98G was around 20% or less of that in IN157 (Abe et al., 1994a). The intracellular level of etoposide in T98G cells in the presence of cepharanthine was only 1.7-fold higher than that in the absence of any agent. However, accumulation of [³H]etoposide increased 2.6- and 3.4-fold in T98G cells line in the presence of verapamil and NIK250 respectively. On the other hand, these reversing agents had no effect on the accumulation of [³H]vincristine in T98G cells (Figure 3).

Figure 2 Northern blots of MRP, MDR1 and DNA topoisomerase I and IIa in four glioma cell lines. RNA (15 μg) from each glioma cell lines was hybridised with various cDNA probes. Ribosomal RNA on the gels is shown after ethidium bromide staining.
The effect of cepharanthine, verapamil and NIK250 on doxorubicin accumulation determined by fluorescence microscopy

Doxorubicin accumulation in T98G cells was compared in the presence and absence of modifiers using fluorescence microscopy. Figure 4 shows that doxorubicin accumulation in the nuclei of untreated T98G cells was lower than that in these cells in the presence of NIK250 when incubated for 40 min with doxorubicin. Doxorubicin in the nuclei of T98G cells was almost completely removed after a further incubation for 120 min in the absence of drug (Figure 4a and b), whereas it remained in the cells when the cells were incubated with NIK250 (Figure 4c and d). We also observed a similar, but lesser effect, when doxorubicin was combined with verapamil, whereas cepharanthine had almost no effect on doxorubicin accumulation in nuclei (Figure 4e–h). The greater inhibition on doxorubicin release from the nuclei might be due to higher affinity of NIK250 to MRP than that of verapamil.

Discussion

NIK250 almost completely reversed drug resistance to vincristine and etoposide in etoposide/tetoposide-resistant cancer cells with a concomitant increase in the cellular accumulation of vincristine or etoposide (Watanabe et al., 1991). This etoposide/tetoposide-resistant cell line (KB/VM-4) derived from human epidermoid cancer KB cells was found to overexpress the MRP, but not the MDRI gene (K Kohn, unpublished data). Consistent with these findings, this study demonstrated that NIK250 modulated drug resistance to etoposide, vincristine and doxorubicin in glioma cells that overexpress MRP (Table I). Verapamil had similar effects to NIK250 in potentiation of those drugs. It remains unknown why drug resistance to doxorubicin in IN500 cells was not completely reversed in the presence of NIK250 or verapamil (Table I). The reversal effect of cepharanthine was only partial in MRP-expressing cells, but almost complete in MDRI-expressing CCF-SSTG1 cells. Both NIK250 and verapamil induced drug resistance reversal effects in both MRP- and P-gp-mediated drug resistance, although cepharanthine had rather a selective effect upon P-gp-mediated drug resistance. MRP shows 15% homology to the MDRI gene (Cole et al., 1992), but NIK250 or verapamil might recognise such a homologous structure in both ATP-binding membranious glycoprotein molecules, resulting in a reversal of multidrug resistance mediated through P-gp and MRP.

NIK250 and verapamil overcame drug resistance to doxorubicin, etoposide and vincristine (Table I). Among the three anti-cancer agents which are potentiated, intracellular accumulation of doxorubicin and etoposide was increased in the presence of these modifiers (Figures 3 and 4), but no apparent accumulation of vincristine was observed (Figure 3). The reversal of vincristine resistance by NIK250 or verapamil in T98G and IN500 cells appeared not to be mediated through enhanced accumulation of this tubulin-targeting anti-cancer agent. Cole et al. (1994) have demonstrated that verapamil and cyclosporin A markedly increase vincristine sensitivity in MRP-transfected cells, but only a slight increase in vincristine accumulation is observed. They suggested that the mechanisms by which verapamil and
cyclosporin A enhance the drug sensitivity of these cells is unlikely to be the result of a direct interaction of these agents with MRP (Cole et al., 1994). Interaction of vincristine with its cellular target, possibly tubulin, might increase the cytotoxicity of the chemosensitising agents themselves – NIK250 and verapamil. However, further studies are required to determine whether this effect is closely involved in their reversal of MRP-mediated vincristine resistance.

Although MRP appears to be closely involved in the acquisition of multidrug resistance in cancer cells (Barrand et al., 1994; Grant et al., 1994), the underlying mechanism of MRP-mediated drug resistance still remains unknown. Calcium antagonists such as verapamil, cyclosporins and other resistance modifiers which can efficiently reverse P-gp-mediated multidrug resistance in vitro show a weak chemosensitising effect, etoposide and adriamycin in human lung cancer cells. Int. J. Cancer, 58, 860 – 864.

References

ABE T., OKAMURA K., ONO M., KOHNO K., MORI T., HOrI S. AND KUWANO M. (1993). Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J. Clin. Invest., 92, 54 – 61.

ABE T., HASEGAWA S., TANIGUCHI K., YOKOMIZO A., KUWANO T., ONO M., MORI T., HOrI S., KOHNO, K. AND KUWANO M. (1994a). Possible involvement of multidrug resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human lung cancer cells. Int. J. Cancer, 58, 860 – 864.

ABE T., MORI T., KOHNO K., SEIKI M., HAYAKAWA T., WELGUS HG, HOrI S. AND KUWANO M. (1994b). Expression of 72-kDa IV collagenase and invasion activity of human glioma cells. Clin. Exp. Metastasis, 12, 296 – 304.

AKIYAMA S., COrNELL MM, KUWANO M., PASTAN I. AND GOTTESMAN MM. (1988). Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vincristine analog. Mol. Pharmacol., 33, 144 – 147.

BARRAND MA, RHODES T., CENTER MS AND TWENTYMAN PR. (1993). Chemosensitisation and drug accumulation effects of cyclosporin A, PSC833 and verapamil in human MDR large cell lung cancer cells expressing a 190 kD membrane protein distinct from P-glycoprotein. Eur. J. Cancer, 29A, 408 – 415.

BARBAYGI, N., KOHNO K., MURAKAMI K., HAYAKAWA A., SUZUKI H., KIRIKO M., KOHNO K. AND KUWANO M. (1992). A 190-kilodalton protein overexpressed in P-glycoprotein-containing multidrug-resistant cell lines and relationship to MRP gene. J. Natl Cancer Inst., 86, 110 – 117.

BRADLEY G., JURANKA PF. AND LING V. (1988). Mechanism of multidrug resistance. Biochim. Biophys. Acta, 948, 87 – 128.

COLE SC, DWONES HF AND SLOVAK ML. (1989). Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumor cell lines which do not overexpress P-glycoprotein. Cancer Res., 49, 40 – 46.

COLE SC, BHARDWAJ G., GERLACH JH, MACKIE JE, GRANT CE, ALMIQUST KC, STEWART AJ, KURZ EU, DUNCAN AM AND DEELEY RG. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650 – 1653.

COLE SC, SPARKS KE, FRASER K., LOE DW, GRANT CE, WILSON GM AND DEELEY RG. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54, 5902 – 5910.

COrNELL MM, PASTAN I. AND GOTTESMAN MM. (1987). Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem., 262, 2162 – 2170.

GOLDSTEIN LJ, GALSki H., FOJO A., WILLINGHAM M., Lai SL, GAZDAZAR A., PIRKER R., GREEN A., COULT W. AND BRODEUR GM. (1989). Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst., 81, 116 – 124.

The variability of chemosensitisation in various MRP-overexpressing cell lines suggests that the mechanisms by which these reversing agents act may depend upon the cell types involved, but this remains to be determined. A relevant study by Rhodes et al. (1994) has demonstrated that inhibitors of H+–ATPase, such as 7-chloro-4-nitrobenz-2-oxa-1,3- diazole and bafilomycin A1, could modify non-P-gp-mediated multidrug resistance in human lung cancer cells. It remains to be determined whether or not dihydropyridine analogues inhibit H+–ATPase.

In conclusion, this study demonstrated that accumulation of etoposide and doxorubicin in T98G cells is enhanced by NIK250 or verapamil, but only slightly, if at all, by cepharanthine. These data suggest that both NIK250 and verapamil can modify both P-gp- and MRP-mediated drug resistance, but that cepharanthine modifies only that mediated by P-gp.

Acknowledgements

This study was supported by a grant-in-aid for cancer research from the Ministry of Education, Science and Culture of Japan. We thank T Nakamura and M Ono in our laboratory for fruitful discussion, and also A Mori in our laboratory for editorial help.
RHODES T, BARRAND MA AND TWENTYMAN PR. (1994). Modification by brefeldin A, bufilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R. Br. J. Cancer, 70, 60–66.

SCHNEIDER E, HORTON JK, YANG MCH, NAKAGAWA M AND COWAN KH. (1994). Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54, 152–158.

SHIRAISHI N, AKIYAMA S, NAKAGAWA M, KOBAYADSHI M AND KUWANO M. (1987). Effect of disbenzylisoquinoline (biscoclaureine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res., 47, 2413–2416.

SLOVAK ML, HOELTGE GA, DALTON WS AND TRENT JM. (1988). Pharmacologic and biologic evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res., 48, 2793.

TSURUO T, IIDA H, TSUKAGOSHI S AND SAKURAI Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967–1972.

WATANABE Y, TAKANO H, KIUE A, KOHNO K AND KUWANO M. (1991). Potentiation of etoposide and vincristine by two synthetic 1,4-dihydropyridine derivatives in multidrug-resistant and atypical multidrug-resistant human cancer cells. Anti-cancer Drug Design, 6, 47–57.

ZAMAN GJ, VERSANTVOORT CH, SMIT JJ, EIJDEMS EW, DE HM, SMITH AJ, BROXTERMAN HJ, MULDER NH, DE VRIE HA, BAAS F AND BORST P. (1993). Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 53, 1747–1750.